San Francisco Business Times: Can Clinical Trials Save California's Stem Cell Agency?
Tippi McKenzie on front page of San Francisco Business Times
Long, difficult and expensive -- that's how the San Francisco Business Times describes stem cell therapy development in an article about the 33 clinical trials currently backed by the $3 billion California stem cell agency.
Will it all prove to be worthwhile? Reporter Ron Leuty addressed the mat…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.